Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06490328
PHASE3
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Sponsor: Dongkook Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Official title: A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Key Details
Gender
MALE
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
154
Start Date
2024-05-30
Completion Date
2025-05-20
Last Updated
2024-07-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
DKF-MA102
Administered twice at 12-week intervals
Locations (1)
Ewha Womans University mokdong Hospital
Seoul, South Korea